var title_f18_62_19424="AML FAB M4EO";
var content_f18_62_19424=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F71045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F71045&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Acute myelomonocytic leukemia (M4EO)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 288px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Bone marrow smear from a patient with acute myelomonocytic leukemia with increased marrow eosinophils (FAB classification M4EO) and an associated inv(16) chromosome abnormality. (Wright-Giemsa stain). The two eosinophilic precursors in this field (arrows) show prominent basophilic-staining granules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     From Brunning, RD, McKenna, RW. Tumors of the bone marrow. Atlas of tumor pathology (electronic fascicle), Third series, fascicle 9, 1994, Washington, DC. Armed Forces Institute of Pathology.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19424=[""].join("\n");
var outline_f18_62_19424=null;
var title_f18_62_19425="Breast MRI of inconclusive mammographic findings - case 1";
var content_f18_62_19425=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F69798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F69798&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Breast MRI of inconclusive mammographic findings - case 1",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 384px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Breast MRI can be useful for problem solving in cases with inconclusive clinical or imaging findings.",
"    <br>",
"     (A) The mammogram shows distortion in the medial right breast, visible only on the CC projection.",
"     <br>",
"      (B) Breast MRI revealed a suspicious irregular enhancing mass in the medial superior breast. Biopsy confirmed invasive lobular carcinoma.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19425=[""].join("\n");
var outline_f18_62_19425=null;
var title_f18_62_19426="Sarcoidosis resembling lichen nitidus";
var content_f18_62_19426=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F73271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F73271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cutaneous sarcoidosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 293px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Flat-topped, round or polygonal papules are present on the neck. In addition, there are multiple 1 to 3 mm round, shiny, skin colored papules in groups at the base of the neck, resembling lichen nitidus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19426=[""].join("\n");
var outline_f18_62_19426=null;
var title_f18_62_19427="Pentetate indium disodium In-111: Patient drug information";
var content_f18_62_19427=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pentetate indium disodium In-111: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/19/5426?source=see_link\">",
"     see \"Pentetate indium disodium In-111: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13185902\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Indium DTPA In 111",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13373857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with a special imaging test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13373814\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560522",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pentetate indium disodium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13373816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13373860\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13373817\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3516872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any skin change.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13373859\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696029",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given into the spine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F13373861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13373818\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 17079 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-110.137.129.113-5655BEDDC5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19427=[""].join("\n");
var outline_f18_62_19427=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13185902\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373857\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373814\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373816\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373860\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373817\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373859\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373861\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13373818\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/19/5426?source=related_link\">",
"      Pentetate indium disodium In-111: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_62_19428="Potassium bicarbonate and potassium citrate (effervescent): Patient drug information";
var content_f18_62_19428=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Potassium bicarbonate and potassium citrate (effervescent): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1748?source=see_link\">",
"     see \"Potassium bicarbonate and potassium citrate (effervescent): Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Effer-K&reg;;",
"     </li>",
"     <li>",
"      Klor-Con&reg;/EF",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10012613\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat low potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10012612\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702765",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to potassium bicarbonate, potassium citrate, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703766",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high potassium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10012617\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696997",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If water pill is stopped, potassium will most often be stopped too. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696686",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid salt substitutes that have potassium, potassium-sparing diuretics, or potassium products.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10012618\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10012620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699117",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weakness, numbness, or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10012615\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695907",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug with food.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4122607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Melt tablet in",
"       <sup>",
"        1",
"       </sup>",
"       /",
"       <sub>",
"        2",
"       </sub>",
"       to 1 cup of cold water or juice and drink.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10012616\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10012621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10012622\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11516 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-61.234.146.186-B1BE4F5CD0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19428=[""].join("\n");
var outline_f18_62_19428=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211765\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012613\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012612\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012617\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012618\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012620\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012615\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012616\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012621\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10012622\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/45/1748?source=related_link\">",
"      Potassium bicarbonate and potassium citrate (effervescent): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_62_19429="Tolvaptan: Patient drug information";
var content_f18_62_19429=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Tolvaptan: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=see_link\">",
"     see \"Tolvaptan: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F7794510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Samsca&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F13276923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Samsca&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026341\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700803",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Start and restart this drug in a hospital setting where your sodium levels will be closely watched. Very bad effects may happen from fixing low sodium levels too fast. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026343\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691940",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat low sodium levels.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026342\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703052",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to tolvaptan or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703825",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have very bad kidney disease or cannot tell when you are thirsty.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701368",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a low sodium level that needs raised right away. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697041",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are dehydrated, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696668",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid grapefruit and grapefruit juice.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698174",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       More thirst.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698027",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dry mouth. Good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help. See a dentist often.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698137",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high blood sugar like confusion, feeling sleepy, more thirst, more hungry, passing urine more often, flushing, fast breathing, or breath that smells like fruit.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698236",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mood changes.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698643",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble swallowing or speaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699098",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble controlling body movements.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026345\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12223 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-6ED53622C5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19429=[""].join("\n");
var outline_f18_62_19429=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7794510\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13276923\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026341\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026343\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026342\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026347\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026348\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026350\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026345\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026346\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026351\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026352\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11654?source=related_link\">",
"      Tolvaptan: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_62_19430="Histoplasma clinical syndromes";
var content_f18_62_19430=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F75641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F75641&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 550px\">",
"   <div class=\"ttl\">",
"    Clinical course following exposure to Histoplasma capsulatum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 530px; height: 706px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histoplasmosis remains asymptomatic in most healthy individuals following low level exposure. Symptomatic infection usually&nbsp;causes self-limited pulmonary illnesses, rheumatologic manifestations, erythema nodosum, or pericarditis, but a heavy inoculum can cause diffuse pulmonary involvement. The variation in clinical course noted in the illustration above depends on the extent of exposure to the organism (ie, ~1 percent of individuals exposed to a low inoculum develop self-limited symptomatic infection compared with ~50 percent of individuals exposed to a high inoculum). Persons with emphysema may develop chronic pulmonary histoplasmosis with cavity formation, and individuals at the extremes of age or with underlying immunosuppressive conditions can develop progressive disseminated disease. Rarely, patients manifest chronic inflammatory conditions such as fibrosing mediastinitis or a sarcoidosis-like illness.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Wheat, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19430=[""].join("\n");
var outline_f18_62_19430=null;
var title_f18_62_19431="What's new in general surgery";
var content_f18_62_19431=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   What's new in general surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/62/19431/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/62/19431/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/62/19431/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/62/19431/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    The following represent additions to UpToDate from the past six months that were considered by the editors and authors to be of particular interest. The most recent What's New entries are at the top of each subsection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     BREAST SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Detection of breast cancer near the nipple areolar complex",
"    </span>",
"   </p>",
"   <p>",
"    For women undergoing mastectomy for breast cancer who wish to preserve the nipple areolar complex (NAC), a nipple sparing procedure may be appropriate for&nbsp;selected cases&nbsp;(eg, unifocal tumor less than 2 cm in diameter, greater than 2 cm from nipple). However, the best way to assess tumor distance from the nipple is not established. &nbsp;MRI was not superior to a clinical breast examination in detecting cancer in or near the NAC in a retrospective review of 71 patients undergoing 77 mastectomy procedures, 23 percent of whom had cancer involving or within 1 cm of the NAC, confirmed histopathologically [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/1\">",
"     1",
"    </a>",
"    ]. The preoperative history and physical examination detected 61 percent of&nbsp;patients with NAC involvement, while&nbsp;MRI detected 56 percent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link&amp;anchor=H7005321#H7005321\">",
"     \"Mastectomy\", section on 'Nipple-sparing mastectomy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=see_link&amp;anchor=H7006000#H7006000\">",
"     \"Mastectomy\", section on 'Choice of mastectomy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Repeat sentinel lymph node dissection after previous axillary procedures",
"    </span>",
"   </p>",
"   <p>",
"    Repeat sentinel lymph node dissection (SLND) in patients with recurrent breast&nbsp;cancer&nbsp;had not been&nbsp;well studied. In a retrospective review of 150 patients with a previous SLND or axillary lymph node dissection (ALND), lymphatic mapping (lymphoscintigraphy) using 99mTc-colloidal albumin identified a sentinel node in 63 percent, and the sentinel node was successfully removed in 52 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/2\">",
"     2",
"    </a>",
"    ]. Micrometastases were identified in 18 patients (23 percent), and a confirmation ALND in all 18 patients identified no additional positive axillary lymph nodes. Thus, repeat SLND&nbsp;appears to be technically feasible, and we suggest use of this procedure in patients who have recurrent breast cancer and previous axillary procedures. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=see_link&amp;anchor=H10349110#H10349110\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\", section on 'Recurrent breast cancer and previous axillary procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Breast tissue density and breast conserving surgery",
"    </span>",
"   </p>",
"   <p>",
"    In a&nbsp;prospective study of&nbsp;1052&nbsp;women undergoing surgery for invasive breast cancer, patients with&nbsp;the highest breast&nbsp;density&nbsp;were significantly&nbsp;less likely to be treated with an initial&nbsp;breast conserving surgery (BCS) compared&nbsp;with&nbsp;those with less dense breast tissue (52 versus&nbsp;74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/3\">",
"     3",
"    </a>",
"    ]. However,&nbsp;breast density was not associated with positive margins&nbsp;on BCS or with conversion to a mastectomy. Thus, breast density should not be a criterion for BCS. In addition,&nbsp;patients with high breast density were more likely to&nbsp;receive a&nbsp;preoperative MRI,&nbsp;although this&nbsp;did not&nbsp;reduce the risk of positive margins.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=see_link&amp;anchor=H8#H8\">",
"     \"Breast conserving therapy\", section on 'Selection criteria for BCT'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Duration of adjuvant tamoxifen for breast cancer",
"    </span>",
"   </p>",
"   <p>",
"    For women taking tamoxifen as adjuvant therapy for breast cancer, the usual recommendation is for a five year course of therapy. However, the results of the Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) trial found that women who took tamoxifen for ten years had a significantly lower risk of recurrence and mortality compared to women who took tamoxifen for five years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/4\">",
"     4",
"    </a>",
"    ]. A longer course of tamoxifen, however, also resulted in a significantly higher incidence of adverse events including endometrial cancer, pulmonary embolus, and ischemic heart disease. Overall, these results support the use of tamoxifen for ten years in women who are tolerating treatment rather than five years. This is particularly true for patients with a relatively higher risk of recurrence based on their tumor characteristics (ie, pathological node involvement, large tumor size, or high tumor grade). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=see_link\">",
"     \"Adjuvant endocrine therapy for hormone receptor-positive breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chemotherapy following resection of a locoregional breast cancer recurrence",
"    </span>",
"   </p>",
"   <p>",
"    The administration of chemotherapy following resection of a locoregional breast cancer recurrence was controversial because of limited data showing a benefit in survival. However, the results of the Chemotherapy as Adjuvant for LOcally Recurrent breast cancer (CALOR) trial, presented at the 2012 San Antonio Breast Cancer Conference, support the use of post-excision (or adjuvant) treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/5\">",
"     5",
"    </a>",
"    ]. In the CALOR trial, patients who underwent surgical resection of locally recurrent breast cancer were randomly assigned to adjuvant chemotherapy or to no treatment. Compared to no treatment, adjuvant chemotherapy resulted in a significant improvement in disease-free (DFS) and overall survival (OS) at five years. However, when stratified by hormone-receptor status, a significant benefit in DFS with adjuvant chemotherapy was reported for women with estrogen receptor (ER)-negative disease, but not ER-positive disease. While only presented in abstract form, these data support the use of chemotherapy in women with breast cancer following resection for locoregional recurrence, particularly for ER-negative disease. We await the full publication to inform the role of adjuvant chemotherapy for women with ER-positive disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30426?source=see_link&amp;anchor=H35227675#H35227675\">",
"     \"Management of locoregional recurrence of breast cancer after mastectomy\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Tamoxifen therapy for men with breast cancer",
"    </span>",
"   </p>",
"   <p>",
"    Five years of tamoxifen is recommended for men diagnosed with hormone receptor-positive breast cancer. Data about compliance in men are limited. In a study of 116 men, adherence rates fell from 65 percent at year 1 to 18 percent by year 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/6\">",
"     6",
"    </a>",
"    ]. Compared with men who were adherent to tamoxifen, low-adherence was associated with significantly lower rates of disease-free survival (42 versus 73 percent) and overall survival (50 versus 80 percent) at 10 years. Significant factors associated with low adherence included age &le;60 years, lack of social support, and adverse effects. Over 60 percent experienced adverse effects, including fatigue, anxiety, sleep disorders, decreased libido, and weight gain. Thus, the tolerability of tamoxifen may significantly limit its efficacy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=see_link&amp;anchor=H954644#H954644\">",
"     \"Breast cancer in men\", section on 'Tamoxifen'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Locoregional recurrence after breast conservation therapy",
"    </span>",
"   </p>",
"   <p>",
"    Repeat breast conserving therapy (BCT) is an investigational alternative to mastectomy for patients who experience a local recurrence. A retrospective study concluded that this approach was appropriate for patients with tumor size &le;2 cm and &gt;48 months to relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/7\">",
"     7",
"    </a>",
"    ]. In this study, 161 patients who were treated with breast conserving surgery for recurrent tumors &le;2 cm and &gt;48 months time to relapse had significantly fewer second recurrences compared with patients with tumors &gt;2 cm and &lt;48 months time to relapse (15.2 versus 31.2 percent). In addition, 71.2 percent of patients with tumors &gt;2 cm treated with repeat breast conserving surgery had a second recurrence, regardless of time to relapse interval. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34650?source=see_link&amp;anchor=H16#H16\">",
"     \"Management of locoregional recurrence of breast cancer after breast conserving therapy\", section on 'Breast conserving surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     HEPATOBILIARY AND UPPER GASTROINTESTINAL SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Multiple pancreatic cysts and risk for high-grade dysplasia or invasive cancer",
"    </span>",
"   </p>",
"   <p>",
"    Typically, pancreatic resection (partial or total) is recommended for patients with pancreatic cysts&nbsp;and features that&nbsp;suggest an increased risk for malignancy&nbsp;(eg, main pancreatic duct dilation to 10 mm or more, mural nodularity, or wall thickening). However, some data suggest that patients with multiple pancreatic cysts may have high-grade dysplasia or invasive carcinoma, even in the absence of worrisome computed tomographic (CT) findings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/8\">",
"     8",
"    </a>",
"    ]. In a retrospective study of 43 patients with &ge;4 pancreatic&nbsp;cysts who underwent resection, 7 patients (16 percent) lacked worrisome CT findings but were found to have high-grade dysplasia or invasive carcinoma on pathologic examination. If these findings are confirmed in prospective studies, it may be reasonable to consider total pancreatectomy for young patients with multiple cysts who are good surgical candidates.&nbsp;(See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=see_link&amp;anchor=H5510679#H5510679\">",
"     \"Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas\", section on 'Surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Blood transfusion thresholds for acute upper GI bleeding",
"    </span>",
"   </p>",
"   <p>",
"    The decision to initiate blood transfusions in patients with acute upper gastrointestinal bleeding is based on the rapidity of bleeding and the patients' comorbid conditions. A randomized trial of patients with and without cardiovascular disease suggests that in patients who are not at increased risk for complications from anemia, outcomes are improved if a lower hemoglobin threshold (&lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    rather than &lt;9",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    is used for initiating blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/9\">",
"     9",
"    </a>",
"    ]. Patients transfused when the hemoglobin was &lt;7",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    had lower mortality rates, were less likely to have further bleeding, and were less likely to suffer complications.",
"    <br/>",
"    <br/>",
"    We recommend giving blood transfusions to maintain the hemoglobin at &ge;7",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    rather than &ge;9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    for the majority of patients with acute upper gastrointestinal bleeding who do not have significant comorbid illnesses. However, patients with active bleeding and hypovolemia may require blood transfusion despite an apparently normal hemoglobin. Additionally, we suggest transfusing to maintain the hemoglobin at &ge;9",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    for patients at increased risk of adverse events in the setting of significant anemia, such as those with unstable coronary artery disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=see_link&amp;anchor=H5079586#H5079586\">",
"     \"Approach to acute upper gastrointestinal bleeding in adults\", section on 'Blood transfusions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=see_link&amp;anchor=H8#H8\">",
"     \"Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction\", section on 'Blood transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PERIOPERATIVE CARE AND ANESTHESIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Bleeding rates with warfarin and dabigatran in atrial fibrillation",
"    </span>",
"   </p>",
"   <p>",
"    Despite favorable results in the initial randomized trials, post-marketing reports have raised concerns that patients with atrial fibrillation may have a higher rate of serious bleeding with dabigatran than warfarin. In November 2012, the US Food and Drug Administration issued a statement that a review of information from insurance claims and administrative data sources suggested that the rate of bleeding with dabigatran did not appear to be higher than with warfarin in patients who were using either drug for the first time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link&amp;anchor=H147982501#H147982501\">",
"     \"Antithrombotic therapy to prevent embolization in atrial fibrillation\", section on 'Studies of anticoagulant monotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hydroxyethyl starch solutions in severe sepsis and septic shock",
"    </span>",
"   </p>",
"   <p>",
"    Randomized trials have demonstrated potential harm from using certain colloid solutions rather than a crystalloid solution in the management of severe sepsis and septic shock. In the Scandinavian Starch for Severe Sepsis and Septic Shock trial, 804 patients with severe sepsis were randomly assigned to receive either 6 percent hydroxyethyl starch (a colloid solution) or Ringer&rsquo;s acetate (a crystalloid solution) at a volume of up to 33",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of ideal body weight per day [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/11\">",
"     11",
"    </a>",
"    ]. When assessed 90 days after randomization, mortality was increased in the hydroxyethyl starch group and more patients in the hydroxyethyl starch group had required renal replacement therapy at some time during their illness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link&amp;anchor=H10#H10\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Intravenous fluids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Hydroxyethyl starch solutions in hypovolemia",
"    </span>",
"   </p>",
"   <p>",
"    Concern has been raised about the potential risks of using hydroxyethyl starch solutions for fluid resuscitation. The validity of this concern was demonstrated in a randomized trial, in which 7000 critically-ill patients were randomly assigned to receive 6% hydroxyethyl starch or isotonic saline for all fluid resuscitation until discharge from the intensive care unit, death, or 90 days&nbsp;post randomization [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/12\">",
"     12",
"    </a>",
"    ]. More patients in the hydroxyethyl starch group required renal replacement therapy, although no difference was found in the risk of death at 90 days in the two groups. Thus, saline solutions are preferred over hydroxyethyl starch solutions for most critically-ill patients with hypovolemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link&amp;anchor=H5#H5\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\", section on 'Colloid versus crystalloid'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Prophylactic versus therapeutic platelet transfusion",
"    </span>",
"   </p>",
"   <p>",
"    To prevent spontaneous bleeding in patients with severe thrombocytopenia from bone marrow suppression, standard practice is to transfuse platelets prophylactically at a specified threshold platelet count (usually",
"    <span class=\"nowrap\">",
"     10,000/microL).",
"    </span>",
"    Two recently completed randomized trials in patients with severe thrombocytopenia due to acute myeloid leukemia, chemotherapy, or autologous hematopoietic cell transplantation have compared this approach with therapeutic transfusion only for active bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Compared with patients who were transfused for a threshold platelet count of",
"    <span class=\"nowrap\">",
"     &le;10,000/microL,",
"    </span>",
"    patients who were only transfused for active bleeding had more frequent episodes of bleeding and more severe bleeding (including fatal intracranial hemorrhage). These results support the current practice of prophylactic platelet transfusion at a threshold platelet count of",
"    <span class=\"nowrap\">",
"     10,000/microL",
"    </span>",
"    in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=see_link&amp;anchor=H323107#H323107\">",
"     \"Clinical and laboratory aspects of platelet transfusion therapy\", section on 'Therapeutic versus prophylactic transfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Coffee for preventing postoperative ileus",
"    </span>",
"   </p>",
"   <p>",
"    Coffee stimulates colonic motility, although whether this effect is related to caffeine or other components in the coffee is unknown. To investigate the potential efficacy of coffee for preventing postoperative ileus, a trial randomly assigned patients to water or coffee following colonic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/15\">",
"     15",
"    </a>",
"    ]. Coffee consumption significantly decreased the time to first bowel movement, time to tolerance of solid food, and time to first flatus compared with water, but the time differences were modest and the clinical benefit uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=see_link\">",
"     \"Postoperative ileus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     VASCULAR SURGERY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Buttonhole cannulation of fistulas and infection",
"    </span>",
"   </p>",
"   <p>",
"    Buttonhole cannulation of arteriovenous fistulas is commonly used for nocturnal or daily hemodialysis. Buttonhole cannulation may be associated with a higher rate of infection compared with conventional &ldquo;rope ladder&rdquo; cannulation. The risk of infection was examined in a randomized trial of 140 conventional hemodialysis patients assigned to either the buttonhole technique or to conventional needling [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/16\">",
"     16",
"    </a>",
"    ]. At eight weeks, the rate of localized infection was higher among patients assigned to the buttonhole technique compared with conventional needling. The degree to which these data from conventional hemodialysis patients may be extrapolated to nocturnal, daily hemodialysis, or self-cannulating patients is not clear [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=see_link&amp;anchor=H13#H13\">",
"     \"Technical aspects of nocturnal hemodialysis\", section on 'Arteriovenous fistulas'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Apixaban for secondary prevention of venous thromboembolism",
"    </span>",
"   </p>",
"   <p>",
"    The randomized, double-blind AMPLIFY-EXT study compared the efficacy and safety of apixaban with placebo in over 2000 subjects with venous thromboembolism (VTE) who had completed 6 to 12 months of anticoagulation and for whom there was uncertainty regarding the further continuation of anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/18\">",
"     18",
"    </a>",
"    ]. Symptomatic recurrent VTE or death from VTE occurred in 8.8 and 1.7 percent of those receiving placebo or apixaban, respectively, for an overall 80 percent reduction in the risk of VTE recurrence with apixaban. Major bleeding was not increased in the group receiving apixaban. A randomized trial comparing this agent with standard-dose warfarin will help to determine the future role of apixaban for the continued treatment of VTE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H7480111#H7480111\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Apixaban'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H30#H30\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Issues to consider'",
"    </a>",
"    .)&nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Aspirin for secondary prevention of venous thromboembolism",
"    </span>",
"   </p>",
"   <p>",
"    Two randomized trials, WARFASA and ASPIRE, examined the use of low-dose aspirin (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for the prevention of recurrent venous thromboembolism (VTE)&nbsp;following&nbsp;6 to 18 months of anticoagulation for a&nbsp;first unprovoked episode of VTE [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. WARFASA showed a significant reduction in the rate of VTE recurrence, in contrast to&nbsp;ASPIRE, which failed&nbsp;to meet&nbsp;its primary end point of significant&nbsp;risk reduction of recurrent&nbsp;VTE.&nbsp;A prospectively planned combined analysis of both trials indicated that aspirin, compared with placebo, significantly reduced both the rate of VTE recurrence and major vascular events (a composite&nbsp;secondary endpoint of&nbsp;recurrent VTE, myocardial infarction, stroke, and cardiovascular death) by 32 and 34 percent, respectively, with no excess bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/20\">",
"     20",
"    </a>",
"    ]. After completing anticoagulant therapy following a first-time unprovoked VTE, switching to low-dose aspirin,&nbsp;is an option that may reduce the risk&nbsp; of VTE recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/21\">",
"     21",
"    </a>",
"    ].&nbsp;Direct comparison of aspirin and warafarin for the prevention of VTE was not performed&nbsp;in either&nbsp;trial and warrants further study. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=see_link&amp;anchor=H11015892#H11015892\">",
"     \"Treatment of lower extremity deep vein thrombosis\", section on 'Use of aspirin'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Ultrasound for surveillance of endovascular aneurysm repair",
"    </span>",
"   </p>",
"   <p>",
"    A systematic review and metaanalysis compared pooled estimates for the sensitivity and specificity of contrast-enhanced ultrasound with unenhanced ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/22\">",
"     22",
"    </a>",
"    ]. Contrast-enhanced ultrasound had a greater sensitivity but lower specificity than unenhanced ultrasound for all endoleaks, but for type I and type III leaks (",
"    <a class=\"graphic graphic_figure graphicRef64707 \" href=\"UTD.htm?36/13/37074\">",
"     figure 1",
"    </a>",
"    ), no differences were found suggesting that the greater sensitivity of contrast-enhanced ultrasound is related to identifying type II endoleak. Since type II endoleak often does not warrant immediate treatment, unenhanced ultrasound may be an adequate study for surveillance following endovascular aneurysm repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=see_link&amp;anchor=H2369876318#H2369876318\">",
"     \"Endovascular repair of abdominal aortic aneurysm\", section on 'Endograft surveillance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     OTHER SURGICAL SPECIALTIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Intraoperative glucocorticoids and tonsillectomy",
"    </span>",
"   </p>",
"   <p>",
"    Intravenous dexamethasone is frequently administered after induction of anesthesia to prevent postoperative nausea and vomiting in children undergoing tonsillectomy. Three recent meta-analyses found no significant difference in the pooled relative risk of any postoperative bleeding between patients receiving dexamethasone and placebo controls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/23-25\">",
"     23-25",
"    </a>",
"    ], although the risk of more severe hemorrhage requiring operative reintervention was higher in the dexamethasone group in one analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/25\">",
"     25",
"    </a>",
"    ]. A randomized trial published subsequent to these meta-analyses found no difference between the dexamethasone and placebo groups in the rates of significant postoperative hemorrhage, although a slightly higher rate of mild, self- or parent-reported postoperative bleeding was seen in the dexamethasone-treated group [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/26\">",
"     26",
"    </a>",
"    ]. The small number of events in the trial limits the ability to draw firm conclusions and further investigation is needed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=see_link&amp;anchor=H11436020#H11436020\">",
"     \"Tonsillectomy and adenoidectomy in children\", section on 'Intraoperative glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Bilateral internal thoracic artery grafting in patients with diabetes",
"    </span>",
"   </p>",
"   <p>",
"    While all patients with diabetes undergoing coronary artery bypass grafting should receive an internal thoracic (mammary) artery (ITA) graft to improve survival, it has been uncertain whether bilateral ITA grafting would add further benefit. Based on the results of two observational studies, which demonstrated significantly higher rates of long-term survival for bilateral ITA grafts compared with single grafts, we suggest that bilateral ITA grafting be performed in many patients with diabetes who require coronary revascularization, particularly those younger than age 70 to 75 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19431/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=see_link&amp;anchor=H22#H22\">",
"     \"Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease\", section on 'Internal thoracic artery grafts'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/1\">",
"      Steen ST, Chung AP, Han SH, et al. Predicting nipple-areolar involvement using preoperative breast MRI and primary tumor characteristics. Ann Surg Oncol 2013; 20:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/2\">",
"      Maaskant-Braat AJ, Roumen RM, Voogd AC, et al. Sentinel Node and Recurrent Breast Cancer (SNARB): results of a nationwide registration study. Ann Surg Oncol 2013; 20:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/3\">",
"      Kapoor NS, Eaton A, King TA, et al. Should breast density influence patient selection for breast-conserving surgery? Ann Surg Oncol 2013; 20:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/4\">",
"      Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2012.",
"     </a>",
"    </li>",
"    <li>",
"     Aebi S, Gelber S, L&aacute;ng I, et al. Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: the CALOR trial (Chemotherapy as Adjuvant for Locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02). 2012 CTRC-AACR San Antonio Breast Cancer Symposium; Abstract S3-2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/6\">",
"      Xu S, Yang Y, Tao W, et al. Tamoxifen adherence and its relationship to mortality in 116 men with breast cancer. Breast Cancer Res Treat 2012; 136:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/7\">",
"      Gentilini O, Botteri E, Veronesi P, et al. Repeating conservative surgery after ipsilateral breast tumor reappearance: criteria for selecting the best candidates. Ann Surg Oncol 2012; 19:3771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/8\">",
"      Raman SP, Kawamoto S, Blackford A, et al. Histopathologic findings of multifocal pancreatic intraductal papillary mucinous neoplasms on CT. AJR Am J Roentgenol 2013; 200:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/9\">",
"      Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med 2013; 368:11.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm282820.htm?source=govdelivery (Accessed on November 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/11\">",
"      Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012; 367:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/12\">",
"      Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med 2012; 367:1901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/13\">",
"      Wandt H, Schaefer-Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic transfusion in patients with haematological malignancies: an open-label, multicentre, randomised study. Lancet 2012; 380:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/14\">",
"      Simon J. Stanworth, Lise Estcourt, Gillian Powter, et al. The Effect of a No-Prophylactic Versus Prophylactic Platelet Transfusion Strategy On Bleeding in Patients with Hematological Malignancies and Severe Thrombocytopenia (TOPPS trial). A Randomized Controlled, Non-Inferiority Trial. American Society of Hematology abstract book 2012; 120:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/15\">",
"      M&uuml;ller SA, Rahbari NN, Schneider F, et al. Randomized clinical trial on the effect of coffee on postoperative ileus following elective colectomy. Br J Surg 2012; 99:1530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/16\">",
"      MacRae JM, Ahmed SB, Atkar R, Hemmelgarn BR. A randomized trial comparing buttonhole with rope ladder needling in conventional hemodialysis patients. Clin J Am Soc Nephrol 2012; 7:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/17\">",
"      Zimmerman D, Lok CE. Accessing the access. Clin J Am Soc Nephrol 2012; 7:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/18\">",
"      Agnelli G, Buller HR, Cohen A, et al. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/19\">",
"      Becattini C, Agnelli G, Schenone A, et al. Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/20\">",
"      Brighton TA, Eikelboom JW, Mann K, et al. Low-dose aspirin for preventing recurrent venous thromboembolism. N Engl J Med 2012; 367:1979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/21\">",
"      Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosis. N Engl J Med 2012; 367:2039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/22\">",
"      Karthikesalingam A, Al-Jundi W, Jackson D, et al. Systematic review and meta-analysis of duplex ultrasonography, contrast-enhanced ultrasonography or computed tomography for surveillance after endovascular aneurysm repair. Br J Surg 2012; 99:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/23\">",
"      Geva A, Brigger MT. Dexamethasone and tonsillectomy bleeding: a meta-analysis. Otolaryngol Head Neck Surg 2011; 144:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/24\">",
"      Shargorodsky J, Hartnick CJ, Lee GS. Dexamethasone and postoperative bleeding after tonsillectomy and adenotonsillectomy in children: A meta-analysis of prospective studies. Laryngoscope 2012; 122:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/25\">",
"      Plante J, Turgeon AF, Zarychanski R, et al. Effect of systemic steroids on post-tonsillectomy bleeding and reinterventions: systematic review and meta-analysis of randomised controlled trials. BMJ 2012; 345:e5389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/26\">",
"      Gallagher TQ, Hill C, Ojha S, et al. Perioperative dexamethasone administration and risk of bleeding following tonsillectomy in children: a randomized controlled trial. JAMA 2012; 308:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/27\">",
"      Dorman MJ, Kurlansky PA, Traad EA, et al. Bilateral internal mammary artery grafting enhances survival in diabetic patients: a 30-year follow-up of propensity score-matched cohorts. Circulation 2012; 126:2935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19431/abstract/28\">",
"      Puskas JD, Sadiq A, Vassiliades TA, et al. Bilateral internal thoracic artery grafting is associated with significantly improved long-term survival, even among diabetic patients. Ann Thorac Surg 2012; 94:710.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16577 Version 2390.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-854D70C629-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19431=[""].join("\n");
var outline_f18_62_19431=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      BREAST SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Detection of breast cancer near the nipple areolar complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Repeat sentinel lymph node dissection after previous axillary procedures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Breast tissue density and breast conserving surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Duration of adjuvant tamoxifen for breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chemotherapy following resection of a locoregional breast cancer recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Tamoxifen therapy for men with breast cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Locoregional recurrence after breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HEPATOBILIARY AND UPPER GASTROINTESTINAL SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Multiple pancreatic cysts and risk for high-grade dysplasia or invasive cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Blood transfusion thresholds for acute upper GI bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PERIOPERATIVE CARE AND ANESTHESIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Bleeding rates with warfarin and dabigatran in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hydroxyethyl starch solutions in severe sepsis and septic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Hydroxyethyl starch solutions in hypovolemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Prophylactic versus therapeutic platelet transfusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Coffee for preventing postoperative ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      VASCULAR SURGERY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Buttonhole cannulation of fistulas and infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Apixaban for secondary prevention of venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Aspirin for secondary prevention of venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Ultrasound for surveillance of endovascular aneurysm repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      OTHER SURGICAL SPECIALTIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Intraoperative glucocorticoids and tonsillectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Bilateral internal thoracic artery grafting in patients with diabetes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/16577\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/16577|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/13/37074\" title=\"figure 1\">",
"      Types of endoleak after endovascular repair",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20106?source=related_link\">",
"      Adjuvant endocrine therapy for hormone receptor-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/55/28538?source=related_link\">",
"      Approach to acute upper gastrointestinal bleeding in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/36/26186?source=related_link\">",
"      Breast cancer in men",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/42/31402?source=related_link\">",
"      Breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/6/20586?source=related_link\">",
"      Clinical and laboratory aspects of platelet transfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30970?source=related_link\">",
"      Coronary artery revascularization in patients with diabetes mellitus and multivessel coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/49/41753?source=related_link\">",
"      Diagnosis and treatment of intraductal papillary mucinous neoplasm of the pancreas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/27/31162?source=related_link\">",
"      Endovascular repair of abdominal aortic aneurysm",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/53/34650?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after breast conserving therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/45/30426?source=related_link\">",
"      Management of locoregional recurrence of breast cancer after mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12586?source=related_link\">",
"      Mastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/33/44569?source=related_link\">",
"      Overview of the non-acute management of unstable angina and non-ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/33/2586?source=related_link\">",
"      Postoperative ileus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/16/264?source=related_link\">",
"      Technical aspects of nocturnal hemodialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/22/35178?source=related_link\">",
"      Tonsillectomy and adenoidectomy in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/4/43082?source=related_link\">",
"      Treatment of lower extremity deep vein thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_62_19432="Prevention of recurrent nephrolithiasis in children";
var content_f18_62_19432=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of recurrent nephrolithiasis in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/62/19432/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/62/19432/contributors\">",
"     Jodi Smith, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/62/19432/contributors\">",
"     F Bruder Stapleton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/62/19432/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/62/19432/contributors\">",
"     Laurence S Baskin, MD, FAAP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/62/19432/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/62/19432/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/62/19432/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 6, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of pediatric nephrolithiasis is divided into two parts.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute episode &ndash; During the acute phase when the stone is being passed, management is directed towards pain control, and facilitating passage or removal of the stone(s).",
"     </li>",
"     <li>",
"      Prevention of recurrent disease &ndash; After the acute episode, management is directed towards prevention of recurrent stone disease. This includes an evaluation to identify any underlying cause or risk factors for stone formation. Based upon this assessment, interventions are tailored to reduce the risk of recurrent stone formation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The prevention of recurrent childhood nephrolithiasis will be reviewed here. The acute management, epidemiology, risk factors, clinical manifestations, and diagnosis of nephrolithiasis in children are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38552?source=see_link\">",
"     \"Acute management of nephrolithiasis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=see_link\">",
"     \"Epidemiology of and risk factors for nephrolithiasis in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13623?source=see_link\">",
"     \"Clinical features and diagnosis of nephrolithiasis in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children and adolescents with nephrolithiasis, renal stones recur frequently. This was illustrated in a large case series of 221 children from the Mayo Clinic that demonstrated two-thirds of the patients developed one or more additional stones at a mean follow-up of 59 months [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19432/abstract/1\">",
"     1",
"    </a>",
"    ]. Other centers have reported a lower but still substantial recurrence rate of 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19432/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The incidence of recurrent nephrolithiasis increases if there is an identified underlying metabolic abnormality that contributes to stone formation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19432/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     RATIONALE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In our practice, we evaluate every child with nephrolithiasis for an underlying metabolic disorder that increases the risk of stone formation. If a metabolic abnormality is detected, we initiate medical therapy to correct the underlying problem. The rationale for our approach is based upon the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Recurrent stone disease frequently occurs in children and adolescents with nephrolithiasis. Children with an underlying metabolic abnormality are more likely to have recurrent stones. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Several case series have demonstrated that over half of the children with nephrolithiasis will have an underlying metabolic abnormality that increases the risk of stone formation [",
"      <a class=\"abstract\" href=\"UTD.htm?18/62/19432/abstract/4\">",
"       4",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=see_link\">",
"       \"Epidemiology of and risk factors for nephrolithiasis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In adults, outcome data demonstrate that medical intervention reduces the rate of recurrent stone disease. Although similar data are not readily available for children, we believe these findings are directly applicable to the prevention of recurrent stones in children. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"       \"Prevention of recurrent calcium stones in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Recurrent episodes of nephrolithiasis are associated with pain, school absenteeism, loss of work hours for the parent(s), and clinical costs. In addition, there is evidence that recurrent stone disease may have long-term deleterious effects upon renal function. (See",
"      <a class=\"local\" href=\"#H22\">",
"       'Outcome'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, prevention of recurrent stone disease should be a major clinical goal. Our practice of minimizing risk factors by identifying and correcting any metabolic abnormality associated with nephrolithiasis is, we believe, a reasonable approach in preventing recurrent disease in children.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EVALUATION FOR UNDERLYING RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the acute episode of stone passage or removal has ended, an evaluation is performed to determine whether there are underlying factors responsible for stone formation. Evaluation includes stone analysis, whenever possible, and an evaluation to detect any underlying metabolic disorder that promotes stone formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Stone analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any stone that is retrieved should be sent to a laboratory with expertise in stone analysis to determine the stone composition. Knowing the composition of the stone can help focus the metabolic evaluation and guide therapeutic decisions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=see_link\">",
"     \"Epidemiology of and risk factors for nephrolithiasis in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H9\">",
"     'Preventive management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Metabolic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, all children with a renal stone should be evaluated for underlying metabolic disorders that increase the risk of stone formation. The metabolic evaluation should be performed while the patient is at home, fully ambulatory, consuming a regular diet, and free of infection. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Rationale'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=see_link&amp;anchor=H3#H3\">",
"     \"Epidemiology of and risk factors for nephrolithiasis in children\", section on 'Overview of risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a stone has been retrieved and analyzed, the evaluation can be focused upon the specific components of the stone. As an example, in a child with calcium oxalate stones, evaluation may be limited to serum measurements of calcium, and urine measurements of oxalate, uric acid, and citrate because hypercalciuria, hyperuricosuria, hyperoxaluria, and hypocitraturia are known risk factors for calcium oxalate stone formation. In this case, urinary measurement of cystine is not necessary.",
"   </p>",
"   <p>",
"    If a stone is not retrieved, we perform a complete metabolic evaluation that consists of both serum and urine testing as discussed in the following sections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Serum tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum testing includes measurements of calcium, phosphorus, bicarbonate, creatinine, magnesium, and uric acid.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient is hypercalcemic or hypophosphatemic, measurement of serum parathyroid hormone levels is required because primary hyperparathyroidism could be the cause of hypercalcemia and renal stones. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical manifestations of primary hyperparathyroidism\", section on 'Nephrolithiasis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of hypophosphatemia raises the possibility of an underlying genetic disorder, such as hypophosphatemic rickets with hypercalciuria. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=see_link&amp;anchor=H16#H16\">",
"       \"Hereditary hypophosphatemic rickets and tumor-induced osteomalacia\", section on 'Hypophosphatemic rickets with hypercalciuria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of a low serum bicarbonate concentration raises the possibility of distal renal tubular acidosis as an underlying cause of nephrolithiasis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=see_link\">",
"       \"Nephrolithiasis in renal tubular acidosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of hypomagnesemia raises the possibility of an underlying genetic disorder, such as familial hypomagnesemia with hypercalciuria and nephrocalcinosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link&amp;anchor=H8658123#H8658123\">",
"       \"Causes of hypomagnesemia\", section on 'Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=see_link\">",
"       \"Causes of hypomagnesemia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The presence of hyperuricemia is seen in lymphoproliferative and myeloproliferative disorders, or rare genetic disorders such as Lesch-Nyhan syndrome (hypoxanthine-guanine phosphoribosyl transferase deficiency), and glycogen storage diseases. However, nephrolithiasis is not generally a presenting finding in these disorders.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Urine tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary abnormalities are best detected by measurements of urinary solute excretion from 24-hour urine collections (",
"    <a class=\"graphic graphic_table graphicRef70589 \" href=\"UTD.htm?19/11/19643\">",
"     table 1",
"    </a>",
"    ). In many laboratories, two or three separate collections are required to obtain all the necessary measurements because different solutes will need to be collected and tested in separate solutions. As examples, uric acid is measured in an alkaline solution, calcium and oxalate in hydrochloric or nitric acid, and citrate in an acidified solution. Clinicians need to check with the clinical laboratory that will be performing the studies to obtain the correct containers and instructions for collection. (See",
"    <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Volume, creatinine, calcium, oxalate, uric acid, sodium and citrate are measured in the 24-hour collections. The measurement of creatinine excretion assesses the completeness of the 24-hour collection. The normal creatinine excretion rate varies by the ratio of lean body mass to total body mass of the individual, which is usually manifested by the age and gender of the patient. Composite normal 24-hour urinary creatinine excretion values based upon age for white children are listed in table 2 (",
"    <a class=\"graphic graphic_table graphicRef80322 \" href=\"UTD.htm?43/17/44315\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19432/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar data for children of other ethnicities are lacking. Until such data exist, we have continued to use the above parameters in all children to check for completion of a 24-hour urine collection. Under collection can be inferred if the creatinine excretion is below the expected normative range and over collection if the creatinine excretion is above the expected normative range.",
"   </p>",
"   <p>",
"    In some cases obtaining a 24-hour urine collection is difficult, especially in infants and small children who are not toilet trained. As a result, normative values based upon a single urine sample have been developed (",
"    <a class=\"graphic graphic_table graphicRef82389 \" href=\"UTD.htm?21/12/21708\">",
"     table 3",
"    </a>",
"    ). Of note, in infants and small children, the solute to creatinine ratios are generally higher in random urine samples because of the lower creatinine excretion rates.",
"   </p>",
"   <p>",
"    Several case series have documented metabolic urine abnormalities in about half of the evaluated children with nephrolithiasis. Specific metabolic findings and their frequency in children with an identifiable metabolic abnormality include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hypercalciuria, 50 percent",
"     </li>",
"     <li>",
"      Hyperoxaluria, 10 to 20 percent",
"     </li>",
"     <li>",
"      Hyperuricosuria, 2 to 8 percent",
"     </li>",
"     <li>",
"      Cystinuria, 5 percent",
"     </li>",
"     <li>",
"      Hypocitraturia, 10 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These metabolic abnormalities and their association with childhood nephrolithiasis are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=see_link&amp;anchor=H4#H4\">",
"     \"Epidemiology of and risk factors for nephrolithiasis in children\", section on 'Metabolic risk factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although urinalysis is performed during the acute presentation and diagnosis of nephrolithiasis, subsequent urinalysis performed when the patient is back to their normal daily routine may be useful in identifying",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    treating modifiable risk factors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A high specific gravity is indicative of a concentrated urine, which increases solute supersaturation and the risk for stone formation.",
"     </li>",
"     <li>",
"      A low urine pH demonstrates an acidic urine, which decreases the solubility of some solutes, such as uric acid and cystine.",
"     </li>",
"     <li>",
"      Crystals detected by examination of the sediment may point towards a specific cause for nephrolithiasis. The presence of hexagonal cystine crystals (",
"      <a class=\"graphic graphic_picture graphicRef56834 \" href=\"UTD.htm?2/10/2208\">",
"       picture 1",
"      </a>",
"      ) is diagnostic of cystinuria, while the presence of phosphate crystals in the urine sediment when the urine pH is above 7 (",
"      <a class=\"graphic graphic_picture graphicRef54594 \" href=\"UTD.htm?34/38/35439\">",
"       picture 2",
"      </a>",
"      ) is suggestive of calcium phosphate or struvite calculi. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=see_link\">",
"       \"Cystine stones\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREVENTIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures are directed towards reducing risk factors associated with stone formation. In adults, clinical trials have demonstrated the benefits of medical therapeutic interventions in reducing new stone formation in patients with underlying metabolic abnormalities. Although similar data are not available for children, we believe the evidence demonstrating beneficial results in adults are directly applicable to the prevention of recurrent stones in children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=see_link&amp;anchor=H12#H12\">",
"     \"Options in the management of renal and ureteral stones in adults\", section on 'Medical therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link\">",
"     \"Risk factors for calcium stones in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Fluid intake",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all children with nephrolithiasis, adequate fluid intake is a key component to reducing the risk of recurrent stones. High fluid intake increases the urine flow rate and lowers the urine solute concentration, thereby reducing the likelihood of new stone formation. Fluid intake is targeted to maintain the following 24-hour urine volumes based upon age [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19432/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infants &ndash; &ge;750 mL",
"     </li>",
"     <li>",
"      Small children below five years of age &ndash; &ge;1000 mL",
"     </li>",
"     <li>",
"      Children between 5 and 10 years of age &ndash; &ge;1500 mL",
"     </li>",
"     <li>",
"      Children greater than 10 years of age &ndash; &ge;2000 mL",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Metabolic interventions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive interventions are targeted to correct specific metabolic abnormalities that increase the risk of stone formation. The most common are briefly reviewed in this section. More complete discussions of many of these disorders are found separately.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hypercalciuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary measures to reduce urinary calcium excretion include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low-sodium diet enhances sodium and calcium renal tubular reabsorption, thereby reducing urinary calcium excretion.",
"     </li>",
"     <li>",
"      Dietary calcium is not restricted and calcium intake is maintained at the United States Recommended Dietary Allowance (USRDA) for age. Calcium restriction below the USRDA is not recommended because of the risk of osteopenia and secondary hyperoxaluria. However, calcium excess should be avoided.",
"     </li>",
"     <li>",
"      Vitamin D supplementation is avoided because elevated serum calcitriol (1,25-dihydroxyvitamin D3) levels can enhance urinary calcium excretion both by increasing intestinal calcium absorption (absorptive hypercalciuria) and by promoting bone resorption (resorptive hypercalciuria).",
"     </li>",
"     <li>",
"      Other measures include limiting animal protein intake to the USRDA, and ensuring adequate potassium intake, as potassium deficiency is associated with increased calcium excretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thiazide diuretics should be considered in a child or adolescent with recurrent calcium stones if dietary measures over a three to six month period fail to reduce urinary calcium levels. Thiazide diuretics (ie,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/27/20919?source=see_link\">",
"     chlorothiazide",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/29/42454?source=see_link\">",
"     hydrochlorothiazide",
"    </a>",
"    ) enhance sodium and calcium reabsorption in the distal renal tubule leading to a reduction in urinary calcium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19432/abstract/7\">",
"     7",
"    </a>",
"    ]. Some patients may benefit from a combination of thiazide diuretics and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?16/58/17317?source=see_link\">",
"     amiloride",
"    </a>",
"    , because amiloride increases calcium reabsorption in the cortical collecting tubule, further lowering calcium excretion. The use of thiazide diuretics in patients with hypercalciuria is discussed in greater detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link&amp;anchor=H13#H13\">",
"     \"Prevention of recurrent calcium stones in adults\", section on 'Hypercalciuria'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=see_link&amp;anchor=H3#H3\">",
"     \"Diuretics and calcium balance\", section on 'Distal tubule and thiazide diuretics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Hyperoxaluria and oxalosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preventive measures in children with idiopathic hyperoxaluria is directed towards diminishing oxalate absorption. The regimen consists of a high fluid intake, oral carbonate or citrate with meals to bind oxalate in the intestinal lumen, and if there is a high oxalate intake, lowering dietary oxalate intake. Oxalate rich foods include beet and turnip greens, rhubarb, strawberries, star fruit, sweet potatoes, wheat bran, tea, cocoa, pepper, chocolate, parsley, beets, spinach, dill, nuts, and citrus juices [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19432/abstract/8\">",
"     8",
"    </a>",
"    ]. Excessive consumption of vitamin C can lead to hyperoxaluria because Vitamin C is metabolized to oxalate.",
"   </p>",
"   <p>",
"    Other therapeutic options, which are generally required for children with secondary hyperabsorption of oxalate due to fat malabsorption include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low-fat diet.",
"     </li>",
"     <li>",
"      Maintain an adequate calcium intake (USRDA). Low calcium intake enhances enteric oxalate absorption.",
"     </li>",
"     <li>",
"      Magnesium and pyrophosphate supplementation. These solutes, when excreted in the urine, inhibit calcium oxalate precipitation.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/27/1462?source=see_link\">",
"       Cholestyramine",
"      </a>",
"      , which binds both intestinal bile acids and oxalate, but side effects may be limiting.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In children with fat malabsorption who have renal stones, appropriate therapy should also be targeted towards correcting the underlying malabsorptive process.",
"   </p>",
"   <p>",
"    Primary hyperoxaluria type I and II are rare autosomal disorders of glyoxalate metabolism that result in increased production of oxalate and hyperoxaluria. Treatment of primary hyperoxaluria is challenging and should be provided by clinicians with expertise in this order. These disorders and their management are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Hyperuricosuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three forms of therapy to reduce urinary uric acid concentration. The first and initial therapy used in any child with hyperuricosuria is increased fluid intake to maintain a targeted 24-hour urine volume based upon the age of the child as previously discussed.",
"   </p>",
"   <p>",
"    The other two measures for those refractory to increased fluid intake include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alkalinization of the urine with administration of potassium citrate or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/26/42402?source=see_link\">",
"       potassium bicarbonate",
"      </a>",
"      , which increases the solubility of uric acid. Alkalinization prevents uric acid precipitation and, in some cases, can lead to dissolution of uric acid crystals and stones. In comparison to the efficacy of potassium bicarbonate or potassium citrate, administration of alkali as the sodium salt may not produce the expected benefit. The sodium-induced volume expansion increases sodium and secondarily calcium excretion resulting in hypercalciuria, which increases the risk of stone formation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=see_link&amp;anchor=H11#H11\">",
"       \"Risk factors for calcium stones in adults\", section on 'Hyperuricosuria'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?24/3/24629?source=see_link\">",
"       allopurinol",
"      </a>",
"      decreases the production of uric acid and is generally reserved for children with a known disorder of uric acid metabolism, such as Lesch-Nyhan syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=see_link&amp;anchor=H10#H10\">",
"       \"Epidemiology of and risk factors for nephrolithiasis in children\", section on 'Hyperuricosuria'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Restriction of dietary purine is of limited value because most children do not consume significant quantities of purine-rich foods, such as anchovies, mussels, and goose brain, kidney and liver. Dietary sodium restriction may decrease uric acid and calcium excretion and reduce the risk of recurrent stone formation.",
"   </p>",
"   <p>",
"    A more complete discussion on the management of uric acid stones is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=see_link\">",
"     \"Uric acid nephrolithiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Cystinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children with cystinuria, the initial conservative therapy used to prevent new stone therapy consists of the following two measures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High fluid intake targeted to reducing the urinary cystine concentration below 250",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"     </li>",
"     <li>",
"      Alkalinization of the urine with administration of potassium citrate or potassium carbonate to achieve a urine pH equal to or above 7.0",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the urine citrate excretion remains elevated despite these measures, cystine-binding drug therapy is recommended. Medications, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/12/21699?source=see_link\">",
"     tiopronin",
"    </a>",
"    , D-penicillamine, and alpha-mercaptoprionlglycine, bind cystine and form highly soluble complexes. These drugs are associated with significant side effects and should be used in consultation with a clinician familiar with their use. In one study of 18 children and young adults with cystinuria, medical therapy including the use of cystine-binding drugs that maintained the urine cystine to creatinine ratio below 0.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.1",
"    <span class=\"nowrap\">",
"     mmol/mmol)",
"    </span>",
"    reduced the formation of new stones from 0.28 to 0.03 per year [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19432/abstract/9\">",
"     9",
"    </a>",
"    ]. In six patients, the size of pre-existing stones was reduced.",
"   </p>",
"   <p>",
"    Cystine stones and their management are discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=see_link\">",
"     \"Cystine stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Hypocitraturia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increasing urinary citrate excretion is the goal in patients with hypocitraturia, because citrate inhibits stone formation by forming a soluble complex with calcium resulting in a reduction of available calcium for binding with oxalate or phosphate. Citrate excretion can be enhanced by alkalinizing the plasma by the daily administration of 30 to 80 mEq of potassium citrate or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/26/42402?source=see_link\">",
"     potassium bicarbonate",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link&amp;anchor=H15#H15\">",
"     \"Prevention of recurrent calcium stones in adults\", section on 'Hypocitraturia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Struvite",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of infection is the main component in reducing the risk of recurrent struvite stones. A complete evaluation of the kidney and urinary tract should also be performed because these children have an increase risk for renal and urinary tract abnormalities that predisposes them to infection and stone formation. Both the evaluation and management of recurrent urinary tract infection and the evaluation of congenital anomalies of the kidney and urinary tract are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=see_link\">",
"     \"Long-term management and prevention of urinary tract infections in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=see_link\">",
"     \"Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Complementary and alternate therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the efficacy and safety of complementary and alternate therapies in the treatment of pediatric nephrolithiasis are not available. Nevertheless, both herbal and acupuncture therapies have commanded widespread interest and use, especially in Asian countries. We do not recommend these therapies as they remain unproven. This discussion is to provide information on what complementary and alternate therapies are being used. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35529?source=see_link&amp;anchor=H15#H15\">",
"     \"Overview of complementary and alternative medicine in pediatrics\", section on 'CAM therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most of the herbal agents used in treating nephrolithiasis are believed to have mild diuretic effects, which may reduce stone formation by increasing urinary flow and volume. Chocolate vine (Mu Tong, Akebia quinata) and Centella asiatica (gotu kola) are traditional Chinese medicine. Kamala (Mallotus philippinensis) and cumin (Cuminum cyminum) are popular treatments in India, although cumin may be of concern in pregnancy because it also is used to induce abortion. Other plants include cleavers (Galium aparine) and burdock (Arctium lappa).",
"   </p>",
"   <p>",
"    Aloe vera and yellow dock (Rumex crispus) contain calcium binders that reduce crystal growth rate, but the high levels of oxalate in yellow dock may negate any beneficial effect.",
"   </p>",
"   <p>",
"    Acupuncture and acupressure are used to treat nephrolithiasis in China.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monitoring includes imaging to detect new stone formation or increasing size of previous stones, and laboratory evaluation to assess the response to preventive medical therapy.",
"   </p>",
"   <p>",
"    The frequency and degree of monitoring in children with nephrolithiasis depends upon the type of stone, the number of stones and recurrence rate, and the presence and severity of any metabolic abnormality. As an example, a child with multiple stones and a significant metabolic problem, such as primary hyperoxaluria or cystinuria, is at greater risk for recurrent nephrolithiasis than a child with a single stone and no evidence of an underlying metabolic abnormality. In the child with a high-risk of recurrent stones, more frequent and intensive monitoring is required.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, ultrasonography is generally used to monitor for new stone formation and change in size of previous stones. Although non-contrast helical computed tomography (CT) is the most sensitive imaging modality in the detection of renal stones, the higher radiation, especially in small children, and cost compared to ultrasonography limits its use in routine follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19432/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of imaging is dependent upon the type and number of stones, and the presence and severity of any underlying metabolic abnormality. In most circumstances and in the absence of symptoms or infections, an examination is performed one year after the initial episode. If the study demonstrates no stone recurrence or change in residual stone size, the study can be performed every other year.",
"   </p>",
"   <p>",
"    Acute symptoms should prompt reevaluation. In this setting, the choice of imaging modality is based upon the clinical circumstances and the availability of appropriate equipment and the expertise of the personnel. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13623?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical features and diagnosis of nephrolithiasis in children\", section on 'Imaging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Metabolic surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;If preventive measures are initiated to correct a metabolic abnormality, subsequent laboratory assessment to evaluate the impact of the intervention is required. In general, we obtain the appropriate studies at six to eight weeks after therapy has begun. If the intervention has successfully corrected the metabolic abnormality, repeat values are obtained at six months, and then at a yearly or every two-year interval. If biochemical abnormalities persist, additional adjustment of the metabolic intervention is required and a subsequent evaluation is needed.",
"   </p>",
"   <p>",
"    If it is difficult to obtain a 24-hour urine collection, random spot urine samples can be obtained.",
"   </p>",
"   <p>",
"    Monitoring the specific gravity of the urinalysis is useful in determining whether increased fluid intake has resulted in a dilute urine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Recurrent stone disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children, there are limited data comparing the effects of metabolic intervention to conservative therapy of increased fluid intake on the rate of stone recurrence. Data that does exist primarily involves children with severe metabolic abnormalities and nephrolithiasis, such as cystinuria and primary hyperoxaluria.",
"   </p>",
"   <p>",
"    As discussed above, in adults there is evidence that dietary measures and some pharmacologic agents decrease recurrent stone formation in patients with the more common metabolic abnormalities of hypercalciuria, hyperoxaluria, and hypocitraturia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=see_link\">",
"     \"Cystine stones\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"     \"Prevention of recurrent calcium stones in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Renal outcome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data are limited regarding the effects of nephrolithiasis upon long-term renal function. The risk of developing chronic renal insufficiency (CRI) and failure (CRF) is primarily dependent upon the presence and severity of an underlying metabolic defect.",
"   </p>",
"   <p>",
"    CRI and CRF frequently develop in patients with severe metabolic disorders, such as primary hyperoxaluria and Dent's disease. Long-term outcome data demonstrate that most patients with cystinuria develop CRI but do not develop CRF. Therapeutic intervention reducing urinary cystine excretion appears to preserve renal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"     \"Primary hyperoxaluria\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=see_link\">",
"     \"Dent's disease (X-linked recessive nephrolithiasis)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=see_link\">",
"     \"Cystine stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Adults with idiopathic calcium oxalate stones have a low risk of renal insufficiency, estimated as 1.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19432/abstract/11\">",
"     11",
"    </a>",
"    ]. The risk for CRI for children with either idiopathic hypercalciuria or hyperoxaluria is unknown. However, renal tubular damage, demonstrated either by increased urinary excretion of N-acetyl-beta-glucosaminidase or impaired renal acidification, has been reported in small case series of children with nephrolithiasis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypercalciuria [",
"    <a class=\"abstract\" href=\"UTD.htm?18/62/19432/abstract/12-14\">",
"     12-14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/26/15779?source=see_link\">",
"       \"Patient information: Kidney stones in children (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In children and adolescents with nephrolithiasis, repeat renal stones occur frequently, with reported recurrence rates between 30 and 60 percent. Children with an underlying metabolic abnormality are more likely to have recurrent stone formation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Over half of children with nephrolithiasis will have an underlying metabolic abnormality. Hypercalciuria is the most common abnormality, followed by hyperoxaluria and hypocitraturia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=see_link\">",
"       \"Epidemiology of and risk factors for nephrolithiasis in children\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest evaluating all children with nephrolithiasis for an underlying metabolic disorder (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Evaluation includes stone analysis, whenever possible, and serum and urine testing to detect increased solute concentrations either in the serum",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      urine. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Rationale'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Evaluation for underlying risk factors'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=see_link\">",
"       \"Prevention of recurrent calcium stones in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Serum testing includes measurements of calcium, phosphorus, bicarbonate, creatinine, magnesium, and uric acid. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Serum tests'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Urinary abnormalities are best detected by measurement of urinary solute excretion from 24-hour urine collections. Volume, creatinine, calcium, oxalate, uric acid, sodium, and citrate are measured in the 24-hour collection. In some cases, obtaining a 24-hour urine collection is difficult, especially in infants and small children who are not toilet trained. As a result, normative values based upon a single urine sample have been developed and complement the age-based standard values for a 24-hour urine collection (",
"      <a class=\"graphic graphic_table graphicRef70589 \" href=\"UTD.htm?19/11/19643\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef82389 \" href=\"UTD.htm?21/12/21708\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Metabolic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend that all children with nephrolithiasis should be instructed to increase their fluid intake (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). We use targeted 24-hour urine volumes based upon age to determine if the fluid intake is adequate. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Fluid intake'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The therapeutic preventive interventions are based upon the underlying metabolic condition as follows for the three most common disorders:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hypercalciuria &ndash; We suggest that children with hypercalciuria be initially managed with dietary measures and not with pharmacologic therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). These measures include a low sodium diet and limiting calcium intake based on the United States Recommended Dietary Allowance for age. We suggest adding thiazide diuretic therapy to a child or adolescent with recurrent calcium stones if dietary measures over a three to six month period fail to reduce urinary calcium levels. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Hypercalciuria'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hyperoxaluria &ndash; We suggest that children with hypercalciuria be initially managed with measures to reduce enteric oxalate absorption (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). These measures include a high fluid intake, oral carbonate or citrate with meals to bind intestinal oxalate, and lowering dietary oxalate intake. Other therapeutic options, such as magnesium and pyrophosphate supplementation or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/27/1462?source=see_link\">",
"       cholestyramine",
"      </a>",
"      , are generally needed in patients with secondary hyperabsorption of oxalate, and not in patients with idiopathic hyperoxaluria. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Hyperoxaluria and oxalosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypocitraturia &ndash; In children with hypocitraturia, we suggest enhancing citrate excretion with administration of potassium citrate or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?41/26/42402?source=see_link\">",
"       potassium bicarbonate",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Hypocitraturia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monitoring includes imaging to detect new stone formation or increasing size of previous stones, and laboratory evaluation to assess the response to preventive medical therapy. Renal ultrasonography is generally used as the imaging modality because of its lower radiation exposure and cost compared to noncontrast helical computed tomography. Ongoing adjustment of the metabolic interventions is based upon the results of laboratory monitoring. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/1\">",
"      Milliner DS, Murphy ME. Urolithiasis in pediatric patients. Mayo Clin Proc 1993; 68:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/2\">",
"      Schwarz RD, Dwyer NT. Pediatric kidney stones: long-term outcomes. Urology 2006; 67:812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/3\">",
"      Pietrow PK, Pope JC 4th, Adams MC, et al. Clinical outcome of pediatric stone disease. J Urol 2002; 167:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/4\">",
"      Spivacow FR, Negri AL, del Valle EE, et al. Metabolic risk factors in children with kidney stone disease. Pediatr Nephrol 2008; 23:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/5\">",
"      Remer T, Neubert A, Maser-Gluth C. Anthropometry-based reference values for 24-h urinary creatinine excretion during growth and their use in endocrine and nutritional research. Am J Clin Nutr 2002; 75:561.",
"     </a>",
"    </li>",
"    <li>",
"     Milliner DS. Urolithiasis. In: Pediatric Nephrology, 5th ed, Avner ED, Harmon WE, Niaudet P (Eds), Lippincott Williams and Wilkins, Philadelphia 2004. p.1091.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/7\">",
"      Choi JN, Lee JS, Shin JI. Low-dose thiazide diuretics in children with idiopathic renal hypercalciuria. Acta Paediatr 2011; 100:e71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/8\">",
"      Nicoletta JA, Lande MB. Medical evaluation and treatment of urolithiasis. Pediatr Clin North Am 2006; 53:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/9\">",
"      Dello Strologo L, Laurenzi C, Legato A, Pastore A. Cystinuria in children and young adults: success of monitoring free-cystine urine levels. Pediatr Nephrol 2007; 22:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/10\">",
"      Brenner D, Elliston C, Hall E, Berdon W. Estimated risks of radiation-induced fatal cancer from pediatric CT. AJR Am J Roentgenol 2001; 176:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/11\">",
"      Gambaro G, Favaro S, D'Angelo A. Risk for renal failure in nephrolithiasis. Am J Kidney Dis 2001; 37:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/12\">",
"      Stapleton FB, Chesney RW, Behrmann AT, Miller LA. Increased urinary excretion of renal N-acetyl-beta-glucosaminidase in hypercalciuria. Am J Dis Child 1985; 139:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/13\">",
"      Bonilla-Felix M, Villegas-Medina O, Vehaskari VM. Renal acidification in children with idiopathic hypercalciuria. J Pediatr 1994; 124:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/62/19432/abstract/14\">",
"      Hamed IA, Czerwinski AW, Coats B, et al. Familial absorptive hypercalciuria and renal tubular acidosis. Am J Med 1979; 67:385.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6109 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-B5D3664DDB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19432=[""].join("\n");
var outline_f18_62_19432=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      RATIONALE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EVALUATION FOR UNDERLYING RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Stone analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Metabolic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Serum tests",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Urine tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREVENTIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Fluid intake",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Metabolic interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hypercalciuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Hyperoxaluria and oxalosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Hyperuricosuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Cystinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Hypocitraturia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Struvite",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Complementary and alternate therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      MONITORING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Metabolic surveillance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Recurrent stone disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Renal outcome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6109\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6109|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/10/2208\" title=\"picture 1\">",
"      Cystine crystals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/38/35439\" title=\"picture 2\">",
"      Struvite crystals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6109|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/11/19643\" title=\"table 1\">",
"      Normal urinary values children 24-hour urine collection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/17/44315\" title=\"table 2\">",
"      Normal creatinine excretion rate for children based upon age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/12/21708\" title=\"table 3\">",
"      Normal urinary solute value in children random urine collection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/41/38552?source=related_link\">",
"      Acute management of nephrolithiasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/41/15000?source=related_link\">",
"      Causes of hypomagnesemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/19/13623?source=related_link\">",
"      Clinical features and diagnosis of nephrolithiasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/19/1338?source=related_link\">",
"      Clinical manifestations of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25577?source=related_link\">",
"      Cystine stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/45/38616?source=related_link\">",
"      Dent's disease (X-linked recessive nephrolithiasis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/39/19061?source=related_link\">",
"      Diuretics and calcium balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/60/6090?source=related_link\">",
"      Epidemiology of and risk factors for nephrolithiasis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/30/32231?source=related_link\">",
"      Evaluation of congenital anomalies of the kidney and urinary tract (CAKUT)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/45/21209?source=related_link\">",
"      Hereditary hypophosphatemic rickets and tumor-induced osteomalacia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/27/7606?source=related_link\">",
"      Long-term management and prevention of urinary tract infections in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/26/23973?source=related_link\">",
"      Nephrolithiasis in renal tubular acidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/62/30695?source=related_link\">",
"      Options in the management of renal and ureteral stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/44/35529?source=related_link\">",
"      Overview of complementary and alternative medicine in pediatrics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/26/15779?source=related_link\">",
"      Patient information: Kidney stones in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38953?source=related_link\">",
"      Prevention of recurrent calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/53/33626?source=related_link\">",
"      Risk factors for calcium stones in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3047?source=related_link\">",
"      Uric acid nephrolithiasis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_62_19433="Nelfinavir: Drug information";
var content_f18_62_19433=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nelfinavir: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/32/43524?source=see_link\">",
"    see \"Nelfinavir: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/31/23033?source=see_link\">",
"    see \"Nelfinavir: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F200394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Viracept&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F200395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Viracept&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F200425\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiretroviral Agent, Protease Inhibitor",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F1671905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral: 750 mg 3 times/day or 1250 mg twice daily with meals in combination with other antiretroviral therapies.",
"     <b>",
"      Note:",
"     </b>",
"     The DHHS Perinatal HIV Guidelines do not recommend the 3 times/day dosing in pregnant women (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F200416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/31/23033?source=see_link\">",
"      see \"Nelfinavir: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      HIV infection:",
"     </b>",
"     Oral: Children 2-13 years: 45-55 mg/kg twice daily",
"     <b>",
"      or",
"     </b>",
"     25-35 mg/kg 3 times/day (maximum: 2500 mg/day). If tablets are unable to be taken, use oral powder in small amount of water, milk (cow&rsquo;s or soy), formula, or dietary supplements; do not use acidic food/juice or store for &gt;6 hours.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F200399\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F200400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No pharmacokinetic data in patients with renal impairment. However, &lt;2% of dose excreted in urine; no dose adjustment is needed.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F200401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dose adjustment necessary in mild impairment (Child-Pugh class A); not recommended in patients with moderate-to-severe impairment (Child-Pugh class B or C)",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F200369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viracept&reg;: 50 mg/g (144 g [DSC]) [contains phenylalanine 11.2 mg/g]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Viracept&reg;: 250 mg, 625 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F200354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F200372\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral powder: Administer reconstituted powder with a meal. Be sure entire contents is consumed to receive full dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablets: Administer with a meal. If unable to swallow tablets, may dissolve tablets in a small amount of water; mix cloudy liquid well and consume immediately. Rinse glass with water to ensure receiving full dose. Tablets may also be crushed and mixed with pudding.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F200370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In combination with other antiretroviral therapy in the treatment of HIV infection",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F200432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Nelfinavir may be confused with nevirapine",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Viracept&reg; may be confused with Viramune&reg;, Viramune&reg; XR&trade;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F200423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Data presented on experience in adults, unless otherwise noted.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Diarrhea (14% to 20%; children: 39% to 47%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     2% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (3% to 7%), flatulence (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Lymphocytes decreased (1% to 6%), neutrophils decreased (1% to 5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Abdominal pain, acute iritis, alkaline phosphatase increased, allergic reaction, amylase increased, anemia, anorexia, anxiety, arthralgia, arthritis, back pain, bilirubinemia, body fat redistribution/accumulation, cramps, creatine phosphokinase increased, dehydration, depression, dermatitis, diaphoresis, dizziness, dyspepsia, dyspnea, emotional lability, epigastric pain, eye disorder, fever, folliculitis, fungal dermatitis, gastrointestinal bleeding, GGTP increased, headache, hepatitis, hyperkinesia, hyper-/hypoglycemia, hyperlipemia; hypersensitivity reaction (bronchospasm, rash, edema); hyperuricemia, immune reconstitution syndrome, insomnia, jaundice, kidney calculus, lactic dehydrogenase increased, leukopenia, lipoatrophy, lipodystrophy, liver function tests abnormal, maculopapular rash, malaise, metabolic acidosis, migraine, mouth ulceration, myalgia, myasthenia, myopathy, pain, pancreatitis, paresthesia, pharyngitis, pruritus, QT",
"     <sub>",
"      c",
"     </sub>",
"     prolongation, rhinitis, seizure, sexual dysfunction, sinusitis, sleep disorder, somnolence, suicidal ideation, thrombocytopenia, torsade de pointes, transaminases increased, urine abnormality, urticaria, vomiting, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F200375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to nelfinavir or any component of the formulation; concurrent therapy with alfuzosin, amiodarone, cisapride, ergot derivatives, lovastatin, midazolam (oral), pimozide, quinidine, rifampin, sildenafil (when used for pulmonary artery hypertension [eg, Revatio&reg;]), simvastatin, St John's wort, triazolam",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F200358\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Fat redistribution: May cause redistribution of fat (eg, buffalo hump, peripheral wasting with increased abdominal girth, cushingoid appearance).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immune reconstitution syndrome: Patients may develop immune reconstitution syndrome resulting in the occurrence of an inflammatory response to an indolent or residual opportunistic infection during initial HIV treatment or activation of autoimmune disorders (eg, Graves&rsquo; disease, polymyositis, Guillain-Barr&eacute; syndrome) later in therapy; further evaluation and treatment may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Changes in glucose tolerance, hyperglycemia, exacerbation of diabetes, DKA, and new-onset diabetes mellitus have been reported in patients receiving protease inhibitors.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hemophilia A or B: Use with caution in patients with hemophilia A or B; increased bleeding during protease inhibitor therapy has been reported.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: May cause hepatitis and/or exacerbate pre-existing hepatic dysfunction; use with caution in patients with underlying hepatic disease, such as hepatitis B or C or cirrhosis; use not recommended with moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; High potential for interactions: Concomitant use of nelfinavir with some drugs may require cautious use, may not be recommended, may require dosage adjustments, or may be contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral powder: Formulation contains phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F200419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2C19 (major), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2B6 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F200363\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abacavir: Protease Inhibitors may decrease the serum concentration of Abacavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: Protease Inhibitors may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ALPRAZolam: Protease Inhibitors may increase the serum concentration of ALPRAZolam.  Management: Concurrent use of alprazolam with indinavir is contraindicated.  All patients receiving such a combination should be monitored closely for excessive response to alprazolam.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Protease Inhibitors may decrease the metabolism of Amiodarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Protease Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Protease Inhibitors may increase the serum concentration of AtorvaSTATin.  Management: Maximum adult atorvastatin doses: 20 mg/day with darunavir/ritonavir, fosamprenavir, fosamprenavir/ritonavir, saquinavir/ritonavir; 40 mg/day with nelfinavir; lowest necessary dose with lopinavir/ritonavir.  Avoid atorvastatin with tipranavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azithromycin (Systemic): Nelfinavir may increase the serum concentration of Azithromycin (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Boceprevir. Management: Avoid initiating coadministration of boceprevir with ritonavir-boosted atazanavir, darunavir, or lopinavir. Monitor for reduced HIV and HCV infection responses when boceprevir is combined with any ritonavir-boosted HIV protease inhibitor regimen.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: May decrease the serum concentration of Nelfinavir. Nelfinavir may increase the serum concentration of Bosentan. Management: Initiate bosentan at, or adjust bosentan dose to, 62.5 mg once daily or every other day (based on tolerability) in patients who receive nelfinavir.  Additionally, monitor for possible reduced clinical response to nelfinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Dihydropyridine).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Nondihydropyridine): Protease Inhibitors may decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade.  Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May increase the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Protease Inhibitors may increase the serum concentration of Cisapride. This may result in QTc prolongation and malignant cardiac arrhythmias.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clarithromycin: Protease Inhibitors may diminish the therapeutic effect of Clarithromycin. Specifically, certain protease inhibitors may decrease formation of the active 14-hydroxy-clarithromycin metabolite, which may negatively impact clarithromycin effectiveness vs. H. influenzae and other non-MAC infections. Clarithromycin may increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Clarithromycin. Clarithromycin dose adjustment in renally impaired patients may be needed.  Management: Avoid clarithromycin doses greater than 1000 mg/day when used with a protease inhibitor. Further dose reductions may be needed in patients with impaired renal function. Consider alternative antimicrobial for any non-MAC infection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Estrogens): Protease Inhibitors may decrease the serum concentration of Contraceptives (Estrogens).  Management: Use oral contraceptives containing at least 35mcg ethinyl estradiol with atazanavir/ritonavir, or no more than 30mcg in patients receiving atazanavir alone. Use of an alternative, non-hormonal contraceptive is recommended with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Delavirdine: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may decrease the serum concentration of Delavirdine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Digoxin: Protease Inhibitors may increase the serum concentration of Digoxin. Increased serum concentrations of digoxin may increase risk of AV nodal blockade.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Divalproex: Protease Inhibitors may decrease the serum concentration of Divalproex.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enfuvirtide: May increase the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Enfuvirtide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Protease Inhibitors may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: Protease Inhibitors may increase the serum concentration of Ergot Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cabergoline.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May increase the serum concentration of Protease Inhibitors. This effect is anticipated with nelfinavir. Protease Inhibitors may decrease the serum concentration of Etravirine. This effect is anticipated with darunavir, saquinavir, and lopinavir (with low-dose ritonavir). Management: Low-dose ritonavir boosting must be used when any protease inhibitor is used with etravirine.  Avoid use of etravirine in combination with atazanavir, fosamprenavir, full-dose ritonavir (600 mg twice daily), or tipranavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fusidic Acid: May decrease the metabolism of Protease Inhibitors. Protease Inhibitors may decrease the metabolism of Fusidic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Garlic: May decrease the serum concentration of Protease Inhibitors. Management: Concurrent use of garlic supplements with protease inhibitors is not recommended.  If this combination is used, monitor closely for altered serum concentrations/effects of protease inhibitors, and particularly for signs/symptoms of therapeutic failure.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Nelfinavir. Concentrations of the active M8 metabolite may also be reduced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May increase the serum concentration of Nelfinavir. Concentrations of the nelfinavir M8 metabolite may also be increased. Nelfinavir may decrease the serum concentration of Lopinavir. Management: Avoid once daily use of lopinavir/ritonavir with nelfinavir.  Avoid use of this combination in patients less than 6 months of age.  See lopinavir/ritonavir prescribing information for recommended dose increases in other patients.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Protease Inhibitors may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Meperidine: Protease Inhibitors may enhance the adverse/toxic effect of Meperidine. Protease Inhibitors may decrease the serum concentration of Meperidine. Concentrations of the toxic Normeperidine metabolite may be increased.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Protease Inhibitors may decrease the serum concentration of Methadone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Protease Inhibitors may increase the serum concentration of Midazolam.  Management: Oral midazolam contraindicated with all protease inhibitors.  IV midazolam contraindicated with fosamprenavir and nelfinavir; other protease inhibitors recommend caution, close monitoring, and consideration of lower IV midazolam doses with concurrent use.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nefazodone: Protease Inhibitors may increase the serum concentration of Nefazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease serum concentrations of the active metabolite(s) of Nelfinavir. Nevirapine may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Nelfinavir may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Protease Inhibitors may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Nelfinavir may decrease the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May increase the serum concentration of other Protease Inhibitors. Management: Atazanavir--indinavir combination contraindicated. Tipranavir/ritonavir or atazanavir/ritonavir not recommended with other protease inhibitors.  Other combos may require dose changes.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease serum concentrations of the active metabolite(s) of Nelfinavir. Proton Pump Inhibitors may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Protease Inhibitors may decrease the metabolism of QuiNIDine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifabutin: Nelfinavir may increase serum concentrations of the active metabolite(s) of Rifabutin. Nelfinavir may increase the serum concentration of Rifabutin. Rifabutin may decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifampin: May decrease the serum concentration of Nelfinavir.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Protease Inhibitors may increase the serum concentration of Rosuvastatin.  Management: Start with the lowest possible rosuvastatin dose and monitor for signs/symptoms of toxicity. In adult patients receiving atazanavir/ritonavir or lopinavir/ritonavir, initiate rosuvastatin at a 5 mg/day and do not exceed a dose of 10 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Protease Inhibitors may increase the serum concentration of Sildenafil.  Management: Erectile dysfunction: sildenafil max = 25 mg/48 hrs with ritonavir, atazanavir, or darunavir; starting dose = 25 mg with other protease inhibitors (adult doses).  Contraindicated if sildenafil being used for pulmonary arterial hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Sildenafil.  Management: When used for treatment of pulmonary arterial hypertension, use of sildenafil with strong CYP3A4 inhibitors should be avoided.  When used for erectile dysfunction, starting dose should be reduced to 25 mg.  Max dose with ritonavir is 25 mg per 48 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Protease Inhibitors may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Protease Inhibitors may increase the serum concentration of Sirolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     St Johns Wort: May increase the metabolism of Protease Inhibitors.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Protease Inhibitors may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Protease Inhibitors may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tadalafil.  Management: Recommendations regarding use of tadalafil in patients also receiving strong CYP3A4 inhibitors may vary based on indication and/or international labeling. Consult appropriate product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Protease Inhibitors may enhance the adverse/toxic effect of Temsirolimus. Levels of sirolimus, the active metabolite, may be increased, likely due to inhibition of CYP-mediated metabolism.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tenofovir: May decrease the serum concentration of Protease Inhibitors. Protease Inhibitors may increase the serum concentration of Tenofovir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Theophylline Derivatives: Protease Inhibitors may decrease the serum concentration of Theophylline Derivatives.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Dyphylline.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraZODone: Nelfinavir may increase the serum concentration of TraZODone.  Management: Consider using a lower dose of trazodone when used in combination with nelfinavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Triazolam: Protease Inhibitors may increase the serum concentration of Triazolam.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: Protease Inhibitors may increase the serum concentration of Tricyclic Antidepressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Valproic Acid: Protease Inhibitors may decrease the serum concentration of Valproic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Protease Inhibitors may increase the serum concentration of Vardenafil.  Management: Limit vardenafil adult dose to max of 2.5 mg/72 hrs with ritonavir, atazanavir, or darunavir; limit to max adult dose of 2.5 mg/24 hrs with other protease inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vardenafil.  Management: Recommendations regarding concomitant use of vardenafil with strong CYP3A4 inhibitors may vary depending on brand name (e.g., Levitra, Staxyn) or by international labeling. Consult appropriate product labeling for specific recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Voriconazole: May increase the serum concentration of Nelfinavir.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Warfarin: Nelfinavir may decrease the serum concentration of Warfarin. Nelfinavir may increase the serum concentration of Warfarin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zidovudine: Protease Inhibitors may decrease the serum concentration of Zidovudine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F200390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Nelfinavir taken with food increases plasma concentration time curve (AUC) by two- to threefold. Do not administer with acidic food or juice (orange juice, apple juice, or applesauce) since the combination may have a bitter taste.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease the levels/effects of protease inhibitors; concurrent use should probably be avoided.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F200365\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F200378\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Nelfinavir crosses the placenta. A modest increased risk of overall birth defects has been observed following first trimester exposure in humans according to data collected by the antiretroviral pregnancy registry. However, no pattern of defects has been detected. The DHHS Perinatal HIV Guidelines recommend nelfinavir to be used only in special circumstances during pregnancy for the prophylaxis of perinatal transmission in antiretroviral-naive women when alternative agents cannot be tolerated. A dose of 1250 mg twice daily has been shown to provide adequate plasma concentrations although lower and variable levels may occur late in pregnancy. A small increased risk of preterm birth has been associated with maternal use of protease inhibitor-based combination antiretroviral (ARV) therapy during pregnancy; however, the benefits of use generally outweigh this risk and protease inhibitors (PIs) should not be withheld if otherwise recommended. Hyperglycemia, new onset of diabetes mellitus, or diabetic ketoacidosis have been reported with PIs; it is not clear if pregnancy increases this risk.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Regardless of CD4 count or HIV RNA copy number, all HIV-infected pregnant women should receive a combination antepartum ARV drug regimen; this includes women who require therapy for their own health, as well as women who do not yet require therapy for their own health. ARV therapy should be started as soon as possible if required for the woman&rsquo;s health. Although earlier initiation may be more effective in reducing the perinatal transmission of HIV, also consider maternal conditions (eg, nausea and vomiting) and the potential risks of first trimester fetal exposure for specific agents. Plasma HIV RNA levels should be assessed at ~34-36 weeks gestation in order to help determine mode of delivery. If ARV therapy must be interrupted for &lt;24 hours during the peripartum period, stop then restart all medications simultaneously in order to decrease the chance of developing resistance. Long-term follow-up is recommended for all infants exposed to ARV medications.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Healthcare providers are encouraged to enroll pregnant women exposed to antiretroviral medications in the Antiretroviral Pregnancy Registry (1-800-258-4263 or www.APRegistry.com). Healthcare providers caring for HIV-infected women and their infants may contact the National Perinatal HIV Hotline (888-448-8765) for clinical consultation (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F200405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F200379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal or infant antiretroviral therapy does not completely eliminate the risk of postnatal HIV transmission. In addition, multiclass-resistant virus has been detected in breast-feeding infants despite maternal therapy. Therefore, in the United States, where formula is accessible, affordable, safe, and sustainable, and the risk of infant mortality due to diarrhea and respiratory infections is low, complete avoidance of breast-feeding by HIV-infected women is recommended to decrease potential transmission of HIV (DHHS [perinatal], 2012).",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F200380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken as scheduled with a meal. Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F200377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Viracept Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     250 mg (300): $1013.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     625 mg (120): $1013.68",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F200367\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function tests, viral load, CD4 count, triglycerides, cholesterol, blood glucose, CBC with differential",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F200381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Elfivir (PE);",
"     </li>",
"     <li>",
"      Nelvir (CO, IN);",
"     </li>",
"     <li>",
"      Viracept (AR, AT, AU, BB, BE, BF, BG, BJ, BM, BR, BS, BZ, CH, CI, CL, CN, CO, CZ, DE, DK, EC, EE, ES, ET, FI, FR, GB, GH, GM, GN, GR, GY, HK, HN, IE, IL, IT, JM, JP, KE, KP, LR, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NL, NO, PH, PL, PT, PY, RU, SC, SD, SE, SG, SK, SL, SN, SR, TH, TN, TR, TT, TZ, UG, UY, VE, ZA, ZM, ZW)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F200357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Binds to the site of HIV-1 protease activity and inhibits cleavage of viral Gag-Pol polyprotein precursors into individual functional proteins required for infectious HIV. This results in the formation of immature, noninfectious viral particles.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F200374\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Food increases AUC of nelfinavir by two- to fivefold",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 2-7 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: &gt;98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via CYP2C19 and 3A4; major metabolite has activity comparable to parent drug",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 3.5-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Feces (98% to 99%, 78% as metabolites, 22% as unchanged drug); urine (1% to 2%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Deeks SG, Smith M, Holodniy M, et al, &ldquo;HIV-1 Protease Inhibitors. A Review for Clinicians,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1997, 277(2):145-53.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents, &ldquo;Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents, Department of Health and Human Services,&rdquo; February 12, 2013;1-267. Available at",
"      <a href=\"file://aidsinfo.nih.gov/Guidelines/GuidelineDetail.aspx?GuidelineID=7&amp;ClassID=1\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      DHHS Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission, \"Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,\"  July 31, 2012. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/lvguidelines/perinatalgl.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Havlir DV and Lange JM, &ldquo;New Antiretrovirals and New Combinations,&rdquo;",
"      <i>",
"       AIDS",
"      </i>",
"      , 1998, 12(Suppl A):165-74.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hilts AE and Fish DN, &ldquo;Dosage Adjustment of Antiretroviral Agents in Patients With Organ Dysfunction,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55:2528-33.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kakuda TN, Struble KA, and Piscitelli SC, &ldquo;Protease Inhibitors for the Treatment of Human Immunodeficiency Virus Infection,&rdquo;",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 1998, 55(3):233-54.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaufman MB and Simionatto C, &ldquo;A Review of Protease Inhibitor-Induced Hyperglycemia,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(1):114-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kaul DR, Cinti SK, Carver PL, et al, &ldquo;HIV Protease Inhibitors: Advances in Therapy and Adverse Reactions, Including Metabolic Complications,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(3):281-98.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      McDonald CK and Kuritzkes DR, &ldquo;Human Immunodeficiency Virus Type 1 Protease Inhibitors,&rdquo;",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1997, 157(9):951-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Perry CM and Benfield P, &ldquo;Nelfinavir,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1997, 54(1):81-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rana KZ and Dudley MN, &ldquo;Human Immunodeficiency Virus Protease Inhibitors,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 1999, 19(1):35-59.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children, &ldquo;Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection,&rdquo; August 16, 2010. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zalma A, von Moltke LL, Granda BW, et al, \"In Vitro Metabolism of Trazodone by CYP3A: Inhibition by Ketoconazole and Human Immunodeficiency Viral Protease Inhibitors,\"",
"      <i>",
"       Biol Psychiatry",
"      </i>",
"      , 2000, 47:655-61.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9685 Version 52.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-A58E39C754-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19433=[""].join("\n");
var outline_f18_62_19433=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200394\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200395\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200425\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1671905\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200416\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200399\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200400\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200401\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200369\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200354\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200372\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200370\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200432\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200423\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200375\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200358\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200419\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200363\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200390\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200365\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200378\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200405\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200379\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200380\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200377\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200367\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200381\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200357\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F200374\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9685\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9685|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/32/43524?source=related_link\">",
"      Nelfinavir: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/31/23033?source=related_link\">",
"      Nelfinavir: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_62_19434="HP bronchiolitis Light";
var content_f18_62_19434=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F73426%7EPULM%2F54489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F73426%7EPULM%2F54489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cellular bronchiolitis in hypersensitivity pneumonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 288px; height: 189px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph shows a cellular bronchiolitis, including peribronchiolar accumulations of giant cells (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchiolitis obliterans",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 333px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Light micrograph showing a polypoid mass of granulation tissue protruding into the bronchiolar lumen and attached to an area where the mucosa is ulcerated. There is fibrotic thickening of the bronchiolar wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Talmadge E King, Jr, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19434=[""].join("\n");
var outline_f18_62_19434=null;
var title_f18_62_19435="Potential independence of effective arterial blood volume from other hemodynamic measures";
var content_f18_62_19435=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F82305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F82305&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential independence of effective arterial blood volume from other hemodynamic measures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Clinical condition",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effective volume",
"       </td>",
"       <td class=\"subtitle1\">",
"        Extracellular volume",
"       </td>",
"       <td class=\"subtitle1\">",
"        Plasma volume",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cardiac output",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        True volume depletion",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Heart failure",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Advanced cirrhosis",
"       </td>",
"       <td>",
"        Decreased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"       <td>",
"        Normal to increased",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <p>",
"     &nbsp;",
"    </p>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19435=[""].join("\n");
var outline_f18_62_19435=null;
var title_f18_62_19436="Common developmental milestones";
var content_f18_62_19436=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F70142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F70142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=9\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Common developmental milestones",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Milestone",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age at acquisition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fixes gaze briefly, habituates to stereotyped auditory, visual, and tactile stimuli",
"       </td>",
"       <td>",
"        At birth (40 weeks post conceptional age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Smiles responsively, gurgles",
"       </td>",
"       <td>",
"        2-3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Visual tracking of a bright object to 180 degrees",
"       </td>",
"       <td>",
"        3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rolls over, holds head upright when pulled from supine to sitting",
"       </td>",
"       <td>",
"        3 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Reaches out for objects",
"       </td>",
"       <td>",
"        4-5 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maintains sitting position independently",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Grasps objects using thumb and index finger pulp",
"       </td>",
"       <td>",
"        8-9 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Crawls, babbles, uses non-specific \"Mama\", \"Dada\" sounds",
"       </td>",
"       <td>",
"        9-10 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pulls up to stand and walks with support",
"       </td>",
"       <td>",
"        10-11 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Walks independently, uses 2-3 clear words, including specific \"Mama\" and \"Dada\"",
"       </td>",
"       <td>",
"        13-14 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Can point to body parts, use simple phrases",
"       </td>",
"       <td>",
"        18-19 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Names body parts, states age, uses phrases",
"       </td>",
"       <td>",
"        24 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pedals tricycle, speaks in sentences, asks questions, likely toilet trained, can name primary colors",
"       </td>",
"       <td>",
"        36 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Masters concepts of alphabets and numbers",
"       </td>",
"       <td>",
"        4-5 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Able to read simple words, add, subtract",
"       </td>",
"       <td>",
"        5-6 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Concepts of division, multiplication, geography, general information like cities, states, large rivers, oceans, etc.",
"       </td>",
"       <td>",
"        7-8 years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Suresh Kotagal.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19436=[""].join("\n");
var outline_f18_62_19436=null;
var title_f18_62_19437="School age children to adol";
var content_f18_62_19437=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F73489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F73489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Dietary recommendations for school-age children to adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Food groups and number of servings",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 9 to 13 years",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age 14 to 18 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Milk and milk products",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Low-fat or fat-free milk or milk products",
"        </em>",
"       </td>",
"       <td>",
"        3 cups/day",
"       </td>",
"       <td>",
"        3 cups/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"2\">",
"        <p>",
"         1 cup equivalent =",
"        </p>",
"        <p>",
"         1 cup of milk or yogurt, 1&frac12; ounces of a natural cheese, 2 ounces of processed cheese, 1/3 cup of shredded cheese",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Meat and other protein foods",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Includes beef, chicken, pork, poultry, fish, eggs, peanut butter, and legumes",
"        </em>",
"       </td>",
"       <td>",
"        5 ounces/day",
"       </td>",
"       <td>",
"        5 to 6 ounces/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"2\">",
"        <p>",
"         1 ounce equivalent =",
"        </p>",
"        <p>",
"         1 ounce of beef, poultry or fish, &frac14; cup cooked beans, 1 egg, 1 tablespoon peanut butter, &frac12; ounce of nuts",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Breads, cereals, and starches",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Includes whole-grain breads, infant and cooked cereals, rice, pasta, ready to eat cereals. Half of all starches should be whole grains.",
"        </em>",
"       </td>",
"       <td>",
"        5 to 6 ounces/day",
"       </td>",
"       <td>",
"        6 to 7 ounces/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"2\">",
"        <p>",
"         1 ounce equivalent =",
"        </p>",
"        <p>",
"         1 slice whole-grain bread, &frac12; cup cooked cereal, rice, or pasta, 1 cup dry cereal",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Fruits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Includes one source of vitamin C daily (citrus fruits and juices, strawberries) and one source of vitamin A every other day (dark green and yellow fruits, melons)",
"        </em>",
"       </td>",
"       <td>",
"        1&frac12; cups/day",
"       </td>",
"       <td>",
"        1&frac12; to 2 cups/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"2\">",
"        <p>",
"         1 cup equivalent =",
"        </p>",
"        <p>",
"         1 cup of fruit or 100 percent fruit juice*, &frac12; cup of dried fruit",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Vegetables",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Includes one source of vitamin C daily (broccoli and tomatoes) and one source of vitamin A every other day (spinach, sweet potatoes, corn, squash)",
"        </em>",
"       </td>",
"       <td>",
"        2 to 2&frac12; cups/day",
"       </td>",
"       <td>",
"        2&frac12; to 3 cups/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"2\">",
"        <p>",
"         1 cup equivalent =",
"        </p>",
"        <p>",
"         1 cup of raw or cooked vegetables or vegetable juice, 2 cups of raw leafy greens",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Fats and oils",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        <em>",
"         Includes margarine, butter, oils",
"        </em>",
"       </td>",
"       <td>",
"        5 teaspoons/day",
"       </td>",
"       <td>",
"        5 to 6 teaspoons/day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"centered\" colspan=\"2\">",
"        <p>",
"         1 teaspoon equivalent =",
"        </p>",
"        <p>",
"         1 teaspoon oil, margarine, butter or mayonnaise, 1 tablespoon salad dressing, sour cream or light mayonnaise",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\">",
"        Miscellaneous",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"3\">",
"        <em>",
"         Desserts, sweets, soft drinks, candy, jams and jelly",
"        </em>",
"       </td>",
"       <td colspan=\"2\">",
"        Limit to small amount, use sparingly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\">",
"        Discretionary calories",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        130 to 410",
"       </td>",
"       <td>",
"        265 to 650",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    NOTE: For more details, go to",
"    <a href=\"file://www.myplate.gov\">",
"     www.myplate.gov",
"    </a>",
"    .",
"    <div class=\"footnotes\">",
"     * Children should be encouraged to consume whole fruits. Recommended to limit fruit juice to 8 to 12 ounces for children 7 to 18 years of age.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Texas Children's Hospital Pediatric Nutrition Reference Guide 2010, 9th Ed. Bunting KD, Mills J, Phillips S et al (eds). Copyright &copy; 2010 Texas Children's Hospital. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19437=[""].join("\n");
var outline_f18_62_19437=null;
var title_f18_62_19438="Paraspinal neurilemmoma CT";
var content_f18_62_19438=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F63818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F63818&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paraspinal neurilemmoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 258px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Large rounded left paraspinal mass originating from an intercostal nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19438=[""].join("\n");
var outline_f18_62_19438=null;
var title_f18_62_19439="Inflammatory morphea";
var content_f18_62_19439=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F57586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F57586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inflammatory morphea",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    An active plaque in the inflammatory stage is present on the left. Note the violaceous border.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_62_19439=[""].join("\n");
var outline_f18_62_19439=null;
